Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of “Moderate Buy” from Analysts
Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target […]
Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target […]
